Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26133200 | 1.00 | PRKCI (0.58) | PRKCITAAR1ESR2ACMSDENPP2 | |
| SCHEMBL38187 | 0.87 | — | — | |
| SCHEMBL30583036 | 0.87 | — | — | |
| SCHEMBL4191589 | 0.87 | PRKCI (0.72) | PRKCIACMSDENPP2CDK8CHRNB4 | |
| SCHEMBL30484286 | 0.86 | PRKCI (0.61) | PRKCITAAR1ESR2ACMSDNPY5R | |
| SCHEMBL20677885 | 0.86 | PRKCI (0.61) | PRKCITAAR1ESR2ACMSDNPY5R | |
| SCHEMBL26037182 | 0.86 | TAAR1 (0.69) | PRKCITAAR1ESR2CYP17A1CYP3A4 | |
| SCHEMBL18297788 | 0.84 | PRKCI (0.76) | PRKCIACMSDENPP2CDK8CYP3A4 | |
| Ethylene SCHEMBL27825931 | 0.83 | TAAR1 (0.52) | PRKCITAAR1ENPP2AGXT | |
| SCHEMBL23750141 | 0.82 | PRKCI (0.67) | PRKCIACMSDENPP2CDK8CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | PRKCI 649/4885TAAR1 4570/4885ESR2 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.